Australia's CSL to Expand U.S. Production

By Stuart Condie

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country.

CSL, which produces plasma-derived therapies for conditions including bleeding disorders and immune deficiencies, on Tuesday said that it expected the investment to create hundreds of jobs.

The plans fit within CSL's existing capital expenditure outlook, which it confirmed this month at an investor day presentation in Chicago. The investment is subject to board approval, CSL said.

"By expanding our onshore production capacity in the U.S., we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the U.S," said Paul McKenzie, CSL's chief executive and managing director.

Manufacturing in the U.S. helps CSL minimize exposure to the Trump administration's tariff announcements, which have hit global pharmaceutical stocks over recent months.

CSL said all its plasma products sold in the U.S. are derived from U.S.-sourced active ingredients.

CSL didn't say where the expanded facilities would be. It currently collects plasma from donors in more than 300 clinics across the U.S. for processing at its facility in Illinois.

The company also has a vaccine facility in North Carolina. Last month, CSL delayed a plan to spin off its flu-vaccine business and cut its annual guidance amid declining vaccination rates in the U.S.

CSL has invested more than $3 billion in its U.S. operations since 2018, increasing the total of employees in the country by more than 50% to almost 19,000. That represents about 65% of CSL's global workforce.

Write to Stuart Condie at stuart.condie@wsj.com

(END) Dow Jones Newswires

November 18, 2025 07:29 ET (12:29 GMT)